Gouty Arthritis (Gout) - Pipeline Review, H1 2018

  • ID: 4537868
  • Report
  • 99 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • C&C Research Laboratories
  • CymaBay Therapeutics Inc
  • Genentech Inc
  • Horizon Pharma Plc
  • Opsona Therapeutics Ltd
  • Rigel Pharmaceuticals Inc
  • MORE
Gouty Arthritis (Gout) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H1 2018, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights:

This latest pipeline guide Gouty Arthritis (Gout) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 11, 1, 19, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • C&C Research Laboratories
  • CymaBay Therapeutics Inc
  • Genentech Inc
  • Horizon Pharma Plc
  • Opsona Therapeutics Ltd
  • Rigel Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Gouty Arthritis (Gout) - Overview

Gouty Arthritis (Gout) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gouty Arthritis (Gout) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development

C&C Research Laboratories

CymaBay Therapeutics Inc

Genentech Inc

Horizon Pharma Plc

Immune Response BioPharma Inc

Jiangsu Hengrui Medicine Co Ltd

Opsona Therapeutics Ltd

Polaris Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

Teijin Pharma Ltd

Wellstat Therapeutics Corp

XL-protein GmbH

Gouty Arthritis (Gout) - Drug Profiles

anakinra - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arhalofenate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-0120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dapansutrile - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

febuxostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FYU-981 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HZN-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation, Neurodegenerative Diseases and Respiratory Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-2110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-2158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-346 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegadricase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REV-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RLBN-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-9350 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-4640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Gout - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit IRAK1/4 for Arthritis and Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Gout - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NLRP3 for Gastrointestinal and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEI-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMX-049 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URC-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

uriSHELS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VERU-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WT-2107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gouty Arthritis (Gout) - Dormant Projects

Gouty Arthritis (Gout) - Discontinued Products

Gouty Arthritis (Gout) - Product Development Milestones

Featured News & Press Releases

Apr 10, 2018: Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress

Apr 03, 2018: Selecta Biosciences to Present Updated Clinical Phase 2 Data of Lead Candidate SEL-212 at the Pan American League of Associations for Rheumatology (PANLAR) Congress

Mar 12, 2018: Takeda Announces Results from Uloric (febuxostat) Cardiovascular Outcomes Trial in Patients with Gout and Cardiovascular Disease

Jan 08, 2018: CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America

Nov 15, 2017: Febuxostat: Drug Safety Communication - FDA to Evaluate Increased Risk of Heart-related Death

Nov 01, 2017: TWi Biotechnology Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting

Oct 11, 2017: Relburn-Metabolomics to Present Developments in Lead Programs for NASH and Gout

Oct 05, 2017: Selecta Biosciences Announces Upcoming Various Clinical and Scientific Presentations on SEL-

Jun 15, 2017: Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout

Jun 06, 2017: Selecta Biosciences Announces Upcoming Clinical Presentations

Jan 11, 2017: First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout

Jan 05, 2017: CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate

Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit

Nov 13, 2016: Results of Study of Febuxostat on the Frequency of Acute Gout Flares in Early Gout

Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Gouty Arthritis (Gout), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H1 2018

Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics Inc, H1 2018

Gouty Arthritis (Gout) - Pipeline by Genentech Inc, H1 2018

Gouty Arthritis (Gout) - Pipeline by Horizon Pharma Plc, H1 2018

Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma Inc, H1 2018

Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Ltd, H1 2018

Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals Inc, H1 2018

Gouty Arthritis (Gout) - Pipeline by Rigel Pharmaceuticals Inc, H1 2018

Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H1 2018

Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Ltd, H1 2018

Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corp, H1 2018

Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H1 2018

Gouty Arthritis (Gout) - Dormant Projects, H1 2018

Gouty Arthritis (Gout) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Gouty Arthritis (Gout) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Gouty Arthritis (Gout), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • C&C Research Laboratories
  • CymaBay Therapeutics Inc
  • Genentech Inc
  • Horizon Pharma Plc
  • Immune Response BioPharma Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Opsona Therapeutics Ltd
  • Polaris Pharmaceuticals Inc
  • Rigel Pharmaceuticals Inc
  • Swedish Orphan Biovitrum AB
  • Teijin Pharma Ltd
  • Wellstat Therapeutics Corp
  • XL-protein GmbH
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll